Cindy Crawford's son died at a Los Angeles rehab facility as investigators await toxicology results, reviving debate over an unproven psychedelic addiction treatment he documented months earlier.
Presley Gerber, the 27-year-old model and only son of Cindy Crawford and Rande Gerber, died Sunday, Sept. 20, 2026, at a rehabilitation facility in Los Angeles. Santa Monica police responded at approximately 9:35 a.m. to a report of a possible overdose in the 1000 block of Berkeley Street, according to reporting carried by Yahoo and other outlets. The Los Angeles County Medical Examiner completed an autopsy the following day but deferred its determination on cause and manner of death pending additional testing, meaning widely circulated descriptions of an overdose remain unconfirmed.
Kit Harington Softens on Jon Snow Spin-Off — Why He Finally Feels Ready to Return
Timeline of the Fatal Sunday and the Deferred Autopsy
Police said there was no indication of foul play, even as the initial emergency dispatch reportedly characterized the incident as a suspected overdose. Dispatch information, cited by TMZ, indicated Gerber suffered cardiac arrest before he died. That detail has not been converted into an official cause of death and should not be treated as confirmation of a drug-related fatality, since the medical examiner's office has stated further studies are required before any determination is released.
The distinction between initial dispatch characterizations and a formal medical finding matters because multiple outlets, including AddictionCenter and Complex, have noted that Gerber had been living at a luxury treatment facility at the time of his death. No official source has yet linked his death to ibogaine, another specific drug, an overdose, or any pre-existing medical condition. Toxicology results, which typically take weeks, had not been released as of the reporting available.
New Found Glory Guitarist Chad Gilbert Dies at 45 — Months After Emergency Brain Surgery
A Public Reckoning With Addiction Captured on Social Media
Gerber had spoken candidly for months about a prolonged struggle with substance use and mental health. Page Six reported that he had taken Valium, buprenorphine and Xanax in the months before his death — medications with distinct clinical purposes, since buprenorphine is typically used to treat opioid-use disorder while Valium and Xanax are benzodiazepines prescribed for anxiety. The available reporting does not specify dosages, timing or whether these medications overlapped, nor does it confirm what, if anything, was present in his system when he died.
In March, Gerber posted a video documenting his preparation for a "pre-ibogaine flood dose" at a wellness clinic in Cancún, Mexico, describing himself as "absolutely terrified" and expressing hope the treatment would help him "find my way back to myself," according to Fox News and other outlets. The post, among his final public reflections on addiction and depression, has taken on new significance following his death, even though roughly six months separate the Mexico treatment from his fatal collapse in Los Angeles.
Dr. Drew Pinsky's Warning and the Cardiac Risk Debate
Fox News reporting highlighted comments from Dr. Drew Pinsky, a physician and addiction specialist, who flagged the treatment setting and absence of conventional medical safeguards as warning signs associated with unregulated ibogaine administration. Pinsky did not treat Gerber, and the available reporting does not establish that ibogaine caused his death; his remarks should be read as expert commentary on risk rather than a finding tied to this specific case.
Ibogaine, a psychoactive compound derived from the root bark of the Central African shrub Tabernanthe iboga, is not approved for medical use in the United States, though some clinics abroad offer it based on preliminary research into its potential for treating withdrawal and opioid dependence. Reporting has associated the substance with cardiovascular dangers, including QT-interval prolongation, a heart-rhythm disturbance that can trigger dangerous ventricular arrhythmias. A 2022 review in the Journal of Substance Abuse Treatment, cited by USA Today, identified 58 ibogaine-associated emergencies — a figure describing reported emergencies, not confirmed deaths, and not evidence that Gerber's treatment caused his.
Family Statements and the Broader Ibogaine Divide
Cindy Crawford was described by People as "heartbroken" over her son's "devastating" death, and family members have asked for privacy as they process the loss. Gerber's former partner, "Summer House" star Lexi Wood, paid tribute to him, saying he had "fought so hard," according to Yahoo's reporting. Gerber was the eldest child of Crawford and nightlife entrepreneur Rande Gerber and the brother of model Kaia Gerber, whose family's public profile has intensified media attention on a death that remains medically unresolved.
The case has also reignited a long-running dispute over ibogaine's place in addiction treatment. An activist quoted by TMZ argued the substance can save lives and should not be judged solely through the circumstances surrounding Gerber's death, reflecting a divide between advocates who view it as a promising intervention and clinicians who point to its limited evidence base, lack of U.S. regulatory approval, and documented cardiac hazards.
What Investigators Still Need to Determine
The Los Angeles County Medical Examiner's next findings, expected once toxicology and additional studies are complete, may clarify whether ibogaine, prescription medications, illicit substances, an underlying cardiac condition, or another factor contributed to Gerber's death. Until then, "suspected overdose" remains an investigative characterization rather than an official conclusion.
No evidence currently available establishes a direct link between Gerber's March ibogaine treatment in Mexico and his September death in Los Angeles, and reporting does not indicate whether he used ibogaine again or what treatment he was undergoing at the time he died. His public documentation of that struggle, however, has renewed scrutiny of how unregulated psychedelic treatments are administered, screened and monitored — a debate authorities' final findings may or may not resolve.
